Señales en vivo de IMRN | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (8 may 2024 @ 16:00):

Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally...

Stats
Volumen de hoy	1 384.00
Volumen promedio	934 780
Capitalización de mercado	15.24M
EPS	$0 ( 2023-08-30 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.56
ATR14	$0 (0.00%)

Immuron Limited Correlación

10 Correlaciones Más Positivas
STER	0.848
DWAC	0.845
VERX	0.843
BAND	0.822
ACMR	0.817
BSQR	0.813

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Immuron Limited Finanzas

Annual	2023
Ingresos:	$1.80M
Beneficio Bruto:	$1.31M (72.54 %)
EPS:	$-0.0166

FY	2023
Ingresos:	$1.80M
Beneficio Bruto:	$1.31M (72.54 %)
EPS:	$-0.0166

FY	2022
Ingresos:	$765 193
Beneficio Bruto:	$523 502 (68.41 %)
EPS:	$-0.0114

FY	2021
Ingresos:	$145 776
Beneficio Bruto:	$94 705.00 (64.97 %)
EPS:	$-1.516

Financial Reports:

No articles found.

Immuron Limited

Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.